Lapatinib Ditosylate Hydrate Drug Due Diligence Report 2026

This Lapatinib Ditosylate Hydrate Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

332

Registered trials

384

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Lapatinib Ditosylate Hydrate can convert its Small molecule drug profile and EGFR x HER2 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Lapatinib Ditosylate Hydrate (query alias: lapatinib)
Modality / target	Small molecule drug; EGFR x HER2; EGFR antagonists, HER2 antagonists
Highest global status	Approved
Originator	GSK Plc
Active developers	Novartis Europharm Ltd., Novartis Pharmaceuticals Corp., Novartis AG

The MCP disease footprint includes Metastatic breast cancer, HER2 Positive Breast Cancer, Breast Cancer. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT05400902	Phase 2	Recruiting	17	Not disclosed
NCT05290116	Phase 2	Recruiting	17	Objective Response Rate
ChiCTR2200061912	Early Phase 1	Pending	80	Troponin I concentration

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

An Open Label, Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative (ER, PR, and HER-2 Negative) Breast Cancer

Not Applicable; n=20; evaluation: not stated. Reported fields: Fatigue = 6 count of participants ; -; -

145eP - Efficacy and safety of lapatinib in comparison with trastuzumab therapy for HER2-positive advanced and metastatic breast cancer

Not Applicable; n=2260; evaluation: Negative. Reported fields: AE(grade 3-5): RR = 1.14(95.0% CI, 0.72 - 1.83), P-Value = 0.57; AE(grade 3-5): RR = 1.14(95.0% CI, 0.72 - 1.83), P-Value = 0.57

Single Arm Phase II Study of Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder as Second Line Treatment

Phase 2; n=15; evaluation: not stated. Reported fields: PFS(Median) = 1.4 months (95% Confidence Interval, 1.1 - 2.1); -; -

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Lapatinib Ditosylate Hydrate addresses Metastatic breast cancer, HER2 Positive Breast Cancer, Breast Cancer. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2014-04-22	GSK completes major three-part transaction with Novartis	Phase 2	US$16,000.0M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Substituted aminobenzyl heteroaryl compounds as EGFR and/or PI3k inhibitors having improved therapeutic index against solid tumors”. The milestone feed surfaced a patent-application signal described as “Combination therapy comprising a KRAS g12d inhibitor and an EGFR inhibitor”. The milestone feed surfaced a patent-application signal described as “EGFR antagonists for the treatment of diseases involving unwanted migration, proliferation, and/or metaplasia of retinal pigment epithelium (RPE) cells”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO